The public health impact of malaria vaccine RTS,S in malaria endemic Africa: Country-specific predictions using 18 month follow-up Phase III data and simulation models

BMC Medicine

Volumn 13, Issue 1, 2015, Pages

  Penny, Melissa A ^a,b   Galactionova, Katya ^a,b   Tarantino, Michael ^a,b   Tanner, Marcel ^a,b   Smith, Thomas A ^a,b  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Malaria; Public health impact; Simulation; Vaccine

Indexed keywords

MALARIA VACCINE;

AFRICA SOUTH OF THE SAHARA; ARTICLE; BAYES THEOREM; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; ENDEMIC DISEASE; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; HEALTH CARE ACCESS; HEALTH IMPACT ASSESSMENT; HEALTH INSURANCE; HUMAN; INCIDENCE; INFANT; MALARIA; MALARIA CONTROL; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PROCESS MODEL; PUBLIC HEALTH; STOCHASTIC MODEL; VACCINATION; ADOLESCENT; ADULT; CLINICAL TRIAL; MALARIA, FALCIPARUM; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AFRICA SOUTH OF THE SAHARA; CHILD; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INFANT; MALARIA; MALARIA VACCINES; MALARIA, FALCIPARUM; MIDDLE AGED; PREVALENCE; PUBLIC HEALTH; TREATMENT OUTCOME; VACCINATION; YOUNG ADULT;

EID: 84937865290     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-015-0408-2     Document Type: Article

References (33)

1. The RTS,S Clinical Trials Partnership 2014. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a Phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med. 2014; 11:1001685.
2. Ballou WR. The development of the RTS,S malaria vaccine candidate: challenges and lessons. Parasite Immunology. 2009; 31:492-500.
3. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, et al.First results of Phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med. 2011; 365:1863-75.
4. Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG, Kabwende AL, et al.A Phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med. 2012; 367:2284-295.
5. Leach A, Vekemans J, Lievens M, Ofori-Anyinam O, Cahill C, Owusu-Agyei S, et al.Design of a Phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa. Malar J. 2011; 10:224.
6. MVI-PATH. "RTS,S Frequently Asked Questions" October 2014. http://www.malariavaccine.org/files/MVI-GSK-FAQ-FINAL-web.pdf .
7. Miller LH, Baruch DI, Marsh K, Doumbo OK. The pathogenic basis of malaria. Nature. 2002; 415:673-9.
8. White MT, Bejon P, Olotu A, Griffin JT, Bojang K, Lusingu J, et al.A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from Phase 2 trials of the RTS,S malaria vaccine. BMC Med. 2014; 12:117.
9. Penny MA, Maire N, Studer A, Schapira A, Smith TA. What should vaccine developers ask? Simulation of the effectiveness of malaria vaccines. PLoS ONE. 2008; 3:3193.
10. Smith T, Killeen GF, Maire N, Ross A, Molineaux L, Tediosi F, et al.Mathematical modeling of the impact of malaria vaccines on the clinical epidemiology and natural history of Plasmodium falciparum malaria: Overview. Am J Trop Med Hyg. 2006; 75:1-10.
11. Smith T, Ross A, Maire N, Chitnis N, Studer A, Hardy D, et al.Ensemble modeling of the likely public health impact of a pre-erythrocytic malaria vaccine. PLoS Med. 2012; 9:1001157.
12. Griffin JT, Hollingsworth TD, Okell LC, Churcher TS, White M, Hinsley W, et al.Reducing Plasmodium falciparum malaria transmission in Africa: a model-based evaluation of intervention strategies. PLoS Med. 2010; 7:1000324.
13. Wenger EA, Eckhoff PA. A mathematical model of the impact of present and future malaria vaccines. Malar J. 2013; 12:126.
14. Tediosi F, Maire N, Penny MA, Studer A, Smith TA. Simulation of the cost-effectiveness of malaria vaccines. Malar J. 2009; 8:127.
15. Tediosi F, Hutton G, Maire N, Smith TA, Ross A, Tanner M. Predicting the cost-effectiveness of introducing a pre-erythrocytic malaria vaccine into the expanded program on immunization in Tanzania. Am J Trop Med Hyg. 2006; 75:131-43.
16. Maire N, Tediosi F, Ross A, Smith T. Predictions of the epidemiologic impact of introducing a pre-erythrocytic vaccine into the expanded program on immunization in sub-Saharan africa. Am J Trop Med Hyg. 2006; 75:111-8.
17. Maire N, Shillcutt SD, Walker DG, Tediosi F, Smith TA. Cost-effectiveness of the introduction of a pre-erythrocytic malaria vaccine into the expanded program on immunization in Sub-Saharan Africa: analysis of uncertainties using a stochastic individual-based simulation model of Plasmodium falciparum malaria. Value Health. 2011; 14:1028-38.
18. Brooks A, Briet OJ, Hardy D, Steketee R, Smith TA. Simulated impact of RTS,S/AS01 vaccination programs in the context of changing malaria transmission. PLoS ONE. 2012; 7:32587.
19. Nunes JK, Cardenas V, Loucq C, Maire N, Smith T, Shaffer C, et al.Modeling the public health impact of malaria vaccines for developers and policymakers. BMC Infect Dis. 2013; 13:295.
20. OpenMalaria. OpenMalaria decay functions 2015. https://github.com/SwissTPH/openmalaria/wiki/ModelDecayFunctions .
21. Gething PW, Patil AP, Smith DL, Guerra CA, Elyazar IR, Johnston GL, et al.A new world malaria map: Plasmodium falciparum endemicity in 2010. Malar J. 2011; 10:378.
22. Olotu A, Fegan G, Wambua J, Nyangweso G, Awuondo KO, Leach A, et al.Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure. N Engl J Med. 2013; 368:1111-20.
23. WHO-UNICEF. accessed 1/6/2014 2014. http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tswucoveragedtp3.html .
24. Lim SS, Stein DB, Charrow A, Murray CJ. Tracking progress towards universal childhood immunisation and the impact of global initiatives: a systematic analysis of three-dose diphtheria, tetanus, and pertussis immunisation coverage. Lancet. 2008; 372:2031-046.
25. Galactionova K, Tediosi F, Savigny Dd, Smith TA, Tanner M. Effective coverage and systems effectiveness for malaria case management in Sub-Saharan African countries. PLoS ONE. 2015; 10:0127818.
26. Ross A, Maire N, Molineaux L, Smith T. An epidemiologic model of severe morbidity and mortality caused by Plasmodium falciparum. Am J Trop Med Hyg. 2006; 75:63-73.
27. Maire N, Smith T, Ross A, Owusu-Agyei S, Dietz K, Molineaux L. A model for natural immunity to asexual blood stages of Plasmodium falciparum malaria in endemic areas. Am J Trop Med Hyg. 2006; 75:19-31.
28. Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG, Hall T, et al.A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS, S/AS02A in malaria-naive adults. Vaccine. 2007; 25:5359-366.
29. Kester KE, Cummings JF, Ockenhouse CF, Nielsen R, Hall BT, Gordon DM, et al.Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS, S/AS02 in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine. 2008; 26:2191-202.
30. Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, Moris P, et al.Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS, S/AS01B and RTS, S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis. 2009; 200:337-46.
31. Aponte JJ, Aide P, Renom M, Mandomando I, Bassat Q, Sacarlal J, et al.Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet. 2007; 370:1543-51.
32. Abdulla S, Agre P, Alonso PL, Arevalo-Herrera M, Bassat Q, Binka F, et al.A research agenda for malaria eradication: vaccines. PLoS Med. 2011; 8:1000398.
33. Seder R, Chang L, Enama M, Zephir K, Sarwar U, Gordon I, et al.Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science. 2013; 341:1359-65.